Jürgen Dittmer

Dr. Jürgen Dittmer

Clinic for Gynecology, University of Halle-Wittenberg, 06120 Halle, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
Jürgen DittmerJürgen Dittmer
Jürgen Dittmer
The Ets1 proto-oncoprotein is a member of the Ets family of transcription factors that share a unique DNA binding domain, the Ets domain. The DNA binding activity of Ets1 is controlled by kinases and transcription factors. Some transcription factors, such as AML-1, regulate Ets1 by targeting its autoinhibitory module. Others, such as Pax-5, alter Ets1 DNA binding properties. Ets1 harbors two phosphorylation sites, threonine-38 and an array of serines within the exon VII domain. Phosphorylation of threonine-38 by ERK1/2 activates Ets1, whereas phosphorylation of the exon VII domain by CaMKII or MLCK inhibits Ets1 DNA binding activity. Ets1 is expressed by numerous cell types. In haemotopoietic cells, it contributes to the regulation of cellular differentiation. In a variety of other cells, including endothelial cells, vascular smooth muscle cells and epithelial cancer cells, Ets1 promotes invasive behavior. Regulation of MMP1, MMP3, MMP9 and uPA as well as of VEGF and VEGF receptor gene expression has been ascribed to Ets1. In tumors, Ets1 expression is indicative of poorer prognosis.

1 December 2015 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Jürgen DittmerJürgen Dittmer
Jürgen Dittmer

1 December 2018 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Jürgen DittmerJürgen Dittmer
Jürgen Dittmer

18 July 2006 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
ADAngela Dittmer
Angela Dittmer
Jürgen DittmerJürgen Dittmer
Jürgen Dittmer

1 April 2015 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Jürgen DittmerJürgen Dittmer
Jürgen Dittmer
BLBenjamin Leyh
Benjamin Leyh

11 April 2014 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
Jürgen DittmerJürgen Dittmer
Jürgen Dittmer
BLBenjamin Leyh
Benjamin Leyh
Stem cells play an important role in tissue repair and cancer development. The capacity to self-renew and to differentiate to specialized cells allows tissue-specific stem cells to rebuild damaged tissue and cancer stem cells to initiate and promote cancer. Mesenchymal stem cells, attracted to wounds and cancer, facilitate wound healing and support cancer progression primarily by secreting bioactive factors. There is now growing evidence that, like mesenchymal stem cells, also tissue-specific and cancer stem cells manipulate their environment by paracrine actions. Soluble factors and microvesicles released by these stem cells have been shown to protect recipient cells from apoptosis and to stimulate neovascularization. These paracrine mechanisms may allow stem cells to orchestrate wound healing and cancer progression. Hence, understanding these stem cell-driven paracrine effects may help to improve tissue regeneration and cancer treatment.